Results 271 to 280 of about 271,187 (352)

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Inflammatory bowel diseases (IBD) require effective therapies to prevent morbidity and maintain quality of life. The introduction of biologic agents, beginning with monoclonal antibodies targeting tumor necrosis factor (TNF) alpha, has launched a new era of advancements that have markedly improved short‐ and long‐term outcomes of Crohn's ...
Lina M. Felipez, Sabina Ali, Edwin F. de Zoeten, Anne M. Griffiths, Sandra C. Kim, Ashish S. Patel, Joel R. Rosh, Jeremy Adler   +7 more
wiley   +1 more source

Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort. [PDF]

Acta Derm Venereol
Jonsson PO, Tayefi M, Svedbom A, Bradley M, Johansson EK.   +4 more
europepmc   +1 more source

A significant number of pediatric inflammatory bowel disease patients are exposed to a medication not approved by the Food and Drug Administration for pediatric use

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Inflammatory bowel disease (IBD) presents before age 20 years in ~25% of patients. Regulatory approvals of IBD medications for pediatric use are often delayed. Nevertheless, many pediatric patients receive medication not approved for pediatric use.
Courtney Rusch, Anthony J. Perkins, Steven J. Steiner, the ImproveCareNow Pediatric IBD Learning Health System   +3 more
wiley   +1 more source

Pharmacists' views on the implementation of therapeutic drug monitoring in oncology

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background There is increasing interest in the potential benefit of therapeutic drug monitoring (TDM) in oncology. However, uptake in Australian hospitals is limited. Aim This study sought to explore hospital pharmacists' experiences with TDM in oncology, seeking to determine if they could provide insights into barriers and facilitators to its
Jane E. Carland, Bridin Murnion, Thomas Sakellaris, Jana Stojanova   +3 more
wiley   +1 more source

Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug. [PDF]

, 2017
Mashayekhi, Arman, Shields, Carol L., Shields, Jerry A., Sioufi, Kareem   +3 more
core   +1 more source

Impact of biologic induction dose and concomitant drugs on anti‐drug antibody formation in a pediatric IBD cohort with high Hispanic representation

JPGN Reports, EarlyView.
Abstract Objectives The use of biologic therapy is increasing in pediatric patients with inflammatory bowel disease (IBD). However, efficacy may be compromised by increased drug clearance and anti‐drug antibodies (ADAs). Historically, concomitant immunomodulator therapy (CIT) has been used to prevent ADA formation. Pediatric studies evaluating CIT have
Kenneth Grant, Jenilee Pohle, Robert Tran, Roy Nattiv   +3 more
wiley   +1 more source

Quantitation of methotrexate polyglutamates in red blood cells and application in patients with Crohn's disease. [PDF]

Transl Clin Pharmacol
Kim H, Kim KS, Kim S, Kang J, Kim HC, Hwang S, Chung JY, Yoon H, Cho JY.   +8 more
europepmc   +1 more source

Hereditary angioedema as a cause of recurrent abdominal pain in a pediatric patient with Crohn's disease

JPGN Reports, EarlyView.
Abstract Hereditary angioedema (HAE) is a rare genetic condition caused by deficient or dysfunctional C1 inhibitor protein (C1INH) resulting in episodic angioedema of the skin, upper airway, and gastrointestinal tract. HAE most often presents within the first two decades of life and may cause severe abdominal pain, nausea, diarrhea, and emesis, making ...
Stephanie L. Rager, Paula J. Busse, Joesph A. Picoraro   +2 more
wiley   +1 more source

Clinical outcomes of anti-inflammatory therapies inhibiting the NLRP3/IL-1β/IL-6/CRP pathway in coronary artery disease patients: a systemic review and meta-analysis of 37,056 individuals from 32 randomized trials. [PDF]

Inflamm Res
Pan Y, Fan F, Jiang J, Zhang Y.
europepmc   +1 more source